Robert B Raffa (R B Raffa, Robert Raffa)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 26

Top Topics

Intimate Partner Violence

Duchenne Muscular Dystrophy

Top Venues

Journal of clinical pharmacy and therapeutics

Postgraduate medicine

Pharmacology research & perspectives

Expert opinion on pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph V Pergolizzi, Prem Fort, Thomas L Miller, Jo Ann LeQuang, Robert B Raffa
The epidemiology of apnoea of prematurity. Journal of clinical pharmacy and therapeutics 47 (5) (2022)
Joseph V Pergolizzi, Robert B Raffa, Guistino Varassi, Peter Magnusson, JoAnn K LeQuang, Antonella Paladini, Robert Taylor, Charles Wollmuth, Frank Breve, Maninder Chopra, Rohit Nalamasu, Paul J Christo
Potential neurological manifestations of COVID-19: a narrative review. Postgraduate medicine (2021)
John F Peppin, Joseph V Pergolizzi, Tong J Gan, Robert B Raffa
The problem of postoperative respiratory depression. Journal of clinical pharmacy and therapeutics 46 (5) (2021)
Joseph V Pergolizzi, Albert Dahan, Jo Ann LeQuang, Robert B Raffa
The conundrum of polysubstance overdose. Journal of clinical pharmacy and therapeutics 46 (5) (2021)
Joseph V Pergolizzi, Guistino Varassi, Peter Magnusson, Frank Breve, Robert B Raffa, Paul J Christo, Maninder Chopra, Antonella Paladini, JoAnn K LeQuang, Kailyn Mitchell, Flaminia Coluzzi
Pharmacologic agents directed at the treatment of pain associated with maladaptive neuronal plasticity. Expert opinion on pharmacotherapy (2021)
Joseph V Pergolizzi, Prem Fort, Thomas L Miller, Jo Ann LeQuang, Robert B Raffa
The limited management options for apnoea of prematurity. Journal of clinical pharmacy and therapeutics (2021)
Joseph V Pergolizzi, Albert Dahan, Jo Ann LeQuang, Robert B Raffa
Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. Journal of clinical pharmacy and therapeutics 46 (6) (2021)
Joseph V Pergolizzi, Lynn R Webster, Eugene Vortsman, Jo Ann LeQuang, Robert B Raffa
Wooden Chest syndrome: The atypical pharmacology of fentanyl overdose. Journal of clinical pharmacy and therapeutics 46 (6) (2021)
John F Peppin, Joseph V Pergolizzi, Albert Dahan, Robert B Raffa
Are opioid receptor antagonists adequate for "Opioid" overdose in a changing reality? Journal of clinical pharmacy and therapeutics 46 (4) (2021)
Joseph V Pergolizzi, Jo Ann LeQuang, Robert B Raffa
Benzodiazepines: Thinking outside the black box. Journal of clinical pharmacy and therapeutics 46 (3) (2020)
Joseph V Pergolizzi, Robert B Raffa, Melanie H Rosenblatt
Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. Journal of clinical pharmacy and therapeutics 45 (5) (2020)
Sumiyo Umeda-Raffa, Joseph V Pergolizzi, Robert B Raffa
Bone fractures during the time of coronavirus. Journal of clinical pharmacy and therapeutics 46 (2) (2020)
Joseph V Pergolizzi, Jo Ann LeQuang, Sumiyo Umeda-Raffa, Charles Fleischer, Joseph Pergolizzi, Claudio Pergolizzi, Robert B Raffa
The Zika virus: Lurking behind the COVID-19 pandemic? Journal of clinical pharmacy and therapeutics 46 (2) (2020)
Robert B Raffa, Robert Taylor, Joseph V Pergolizzi
Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions. Journal of clinical pharmacy and therapeutics 44 (3) (2019)
Jan M Kitzen, Jamie L McConaha, Megan L Bookser, Joseph V Pergolizzi, Robert Taylor, Robert B Raffa
e-Cigarettes for smoking cessation: Do they deliver? Journal of clinical pharmacy and therapeutics 44 (4) (2019)
Thomas Christoph, Robert B Raffa, Jean De Vry, Wolfgang Schröder
Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model. Pharmacology research & perspectives 6 (6) (2018)
Joseph V Pergolizzi, Robert Taylor, JoAnn K LeQuang, Robert B Raffa, null null
The role and mechanism of action of menthol in topical analgesic products. Journal of clinical pharmacy and therapeutics 43 (3) (2018)
U J Eke-Okoro, Robert B Raffa, J V Pergolizzi, F Breve, Robert Taylor, null null
Curcumin in turmeric: Basic and clinical evidence for a potential role in analgesia. Journal of clinical pharmacy and therapeutics 43 (4) (2018)
Robert B Raffa, Joseph V Pergolizzi, Robert Taylor, M H Ossipov, null null
Nature's first "atypical opioids": Kratom and mitragynines. Journal of clinical pharmacy and therapeutics 43 (3) (2018)
Robert B Raffa, Joseph V Pergolizzi, Robert Taylor, Jan M Kitzen, null null
Sunscreen bans: Coral reefs and skin cancer. Journal of clinical pharmacy and therapeutics 44 (1) (2018)
Robert B Raffa, J V Pergolizzi, Robert Taylor, M H Ossipov, null null
Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs). Journal of clinical pharmacy and therapeutics 43 (4) (2018)
Robert B Raffa, Joseph V Pergolizzi, Robert Taylor, Michael H Ossipov, null null
Discovery of "folded DNA" structures in human cells: Potential drug targets. Journal of clinical pharmacy and therapeutics 44 (1) (2018)
Robert B Raffa, J V Pergolizzi, Robert Taylor, null null
The rapid-onset antidepressant effect of ketamine: More surprises? Journal of clinical pharmacy and therapeutics 43 (2) (2017)
Robert B Raffa, J V Pergolizzi, JoAnn K LeQuang, Robert Taylor, null null, S Colucci, M H Annabi
The fentanyl family: A distinguished medical history tainted by abuse. Journal of clinical pharmacy and therapeutics 43 (1) (2017)
J V Pergolizzi, J A LeQuang, R Taylor, Robert B Raffa, null null
The "Darknet": The new street for street drugs. Journal of clinical pharmacy and therapeutics 42 (6) (2017)
S E Strasburger, P M Bhimani, J H Kaabe, J T Krysiak, D L Nanchanatt, T N Nguyen, K A Pough, T A Prince, N S Ramsey, K H Savsani, L Scandlen, M J Cavaretta, Robert B Raffa
What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. Journal of clinical pharmacy and therapeutics 42 (2) (2017)